Introduction
Although B cell chronic lymphocytic leukemia (B-CLL) has been traditionally viewed as a tumor of virgin B cells, this notion has been recently questioned by data suggesting that a fraction of B-CLL derives from antigen experienced B cells. In fact, the malignant cells of approximately 50% B-CLL express somatically mutated IgV genes. [1] [2] [3] [4] Since accumulation of IgV gene mutations occurs primarily in the germinal centers (GC) following B cell encounter with the specific antigen, 5 it has been proposed that a major a fraction of B-CLL cases originate from post-GC, memory B cells.
In addition to mutations of Ig genes, the GC microenvironment allows for somatic mutations to take place in other loci, namely the BCL-6 proto-oncogene. 6, 7 The sequences affected by mutations lie in the proximity of the BCL-6 promoter and overlap with the major cluster of chromosomal breakpoints. [7] [8] [9] [10] [11] [12] Mutations of BCL-6 usually affect the 5Ј untranslated region, are often multiple in the same tumor, may be biallelic, and occur independently of cytogenetic alterations of band 3q27. 7, [13] [14] [15] [16] [17] Mutations of BCL-6 are regarded as a marker of B cell transit through the GC because, in normal lymphoid tissues, they occur in approximately 30 to 50% of GC and memory B cells. [13] [14] [15] Among B cell neoplasms, BCL-6 mutations occur in non-Hodgkin lymphomas known to originate from GC or post-GC B cells, but not in tumors of precursor and virgin B cells. 7, [13] [14] [15] [16] [17] [18] Because BCL-6 mutations provide a new molecular marker for defining the histogenesis of a given B cell neoplasm, we aimed at defining their distribution in B-CLL and at comparing it with the distribution of IgV mutations in the same tumor panel. Our data show that a fraction of B-CLL harbor BCL-6 and/or IgV genes mutations, thus reinforcing the notion that the histogenesis of this leukemia is heterogeneous and that a substantial subgroup of B-CLL derive from post-germinal center B cells.
Materials and methods

B-CLL samples and DNA/RNA extraction
Twenty-eight patients with clinical features of B-CLL were randomly chosen among a large collection of 145 patients. Peripheral blood of these patients showed expansion of cells with the typical phenotype of B-CLL. Cells were CD19, CD5, CD23 positive and CD22 negative. Expression of CD79b was low or absent. The fraction of neoplastic cells varied from 80 to 95% of peripheral blood mononuclear cells (PBMNC).
Genomic DNA was purified by cell lysis followed by digestion with proteinase K, 'salting out' extraction and precipitation by ethanol. 19, 20 Total RNA was isolated from B-CLL samples using a commercial kit (RNA Clean; TIB MolBiol, Genoa, Italy) according to the manufacturer's instructions.
Nucleotide sequence analysis of BCL-6
The oligonucleotides used as primers for the analysis of BCL-6 5Ј non-coding regions were as follows: E1.21B, 5Ј-CTCTTGCCAAATGCTTTG-3Ј and E1.26, 5Ј-CACGAT-ACTTCATCTCATC-3Ј. These oligonucleotides amplify a PCR product spanning a 739 bp region located downstream of the first noncoding exon of BCL-6 and containing Ͼ95% of BCL-6 mutations occurring in human neoplasms. 7, [13] [14] [15] [16] [17] [18] Direct sequencing of the amplified PCR fragment was performed with the primers indicated above, or with internal primers, using a commercially available kit (ThermoSequenase; Amersham Life Science, Milan, Italy). ␣-33 P-labeled terminator dideoxynucleotides (Amersham Life Science) were included in the sequencing mixture. For each DNA fragment analyzed, sequencing of both strands was performed on independent PCR products. When encountered, population polymorphisms Leukemia of the BCL-6 DNA sequence were ruled out from the calculation of the frequency of mutation. 7 PCR products showing mutations by direct sequencing were cloned using the TA vector cloning kit (Invitrogen, Leek, The Netherlands) following the manufacturer's instructions. For each patient harboring mutations, at least five clones were sequenced using the PE Applied Biosystems automated sequenator.
BCL-6 protein immunostaining
5 × 10 5 B-CLL cells were fixed in 1% paraformaldehyde for 1 h at 4°C and then washed with PBS and permeabilized in 0.05% Tween 20 for 15 min at room temperature. Subsequently, cells were washed and stained with BCL-6 moAb (clone F1F6 (␥1 isotype), Walter Occhiena, Torino, Italy) or with the appropriate control (␥1 mouse antibody (Becton Dickinson Italia, Milan, Italy)). The secondary reagent used was an anti-mouse ␥1 FITC (Southern Biotechnology, Birmingham, UK). The antibody PG-B6p, used in some experiments, was kindly donated by Dr B Falini (University of Perugia). 21 A Burkitt's lymphoma cell line (BRG-A), obtained and cultered as reported, 22 was used as a positive control for BCL-6 expression. Antibodies were incubated for 20 min at 4°C and cells were washed and resuspended in 200 l of cold PBS before analysis with FACStar (Becton Dickinson Italia) using CellQuest software.
Preparation of templates and conditions for PCR amplification of Ig genes
Two g of RNA were reverse transcribed to cDNA using M-MLV reverse transcriptase (GIBCO BRL, Life Technologies, Milan, Italy) primed by an oligo dT (16mer) primer. These reactions were carried out in 25 l using 50 pmoles of primer at 42°C for 1 h.
To determine the nucleic acid sequence of V H and V L genes, 2 l of cDNA from each B-CLL sample were amplified using a sense V H or V L leader family-specific primer in conjunction with the appropriate antisense IgM, IgG, IgA, Ck or C primer. Sequence of primers and PCR conditions have been reported previously. 1, 23 Because of the lack of an amplification product in some B-CLL samples (cases 05, 16 and 23), the V H leaderspecific primers were replaced by V H FR1 primers (reported in Ref. 1) or by the following V H FR2 primers: 3.11, 5Ј-GDT CCG CCA GGC TCC AG-3Ј and 3.12, 5Ј-GGT CCG SCA AGC TCC AG-3Ј. The V H or V L PCR products were sequenced directly after ethanol precipitation using an automated sequenator (PE Applied Biosystems, Monza, Italy). The rate of Taq misincorporation, evaluated in our laboratory, was of 1 bp every 800 bp. Two independently generated PCR products were sequenced in each sample. Nucleotide sequences have been submitted in EMBL under the following accession numbers: AJ388639-AJ388666, AJ389169-389196.
Analyses of V H and V L sequences
V H and V L sequences obtained from B-CLL cases were compared with the V BASE sequence directory (MRC Centre for Protein Engineering, Cambridge, UK) using MacVector 6.0.1 software (Oxford Molecular Group, Oxford, UK).
Results
Analysis of BCL-6 mutations in B-CLL
Mutations of BCL-6 were detected in 10/28 (36%) B-CLL cases (Table 1 ). In total, 18 mutational events were observed among the 10 mutated samples. Table 1 summarizes the characteristics of the BCL-6 mutations detected in B-CLL. In 9/10 mutated cases, mutations occurred in only one allele, whereas in one B-CLL (case 1) both alleles carried BCL-6 mutations. Mutations were almost exclusively represented by single nucleotide substitutions, with only one being a single base insertion. The average frequency of mutation was 0.209 × 10 −2 bp (range: 0.135-0.541 × 10 −2 /bp, corresponding to 1-4 mutations per allele). The observed transition/transversion ratio was 0.7 and mutations targeted all four nucleotides with no significant differences in frequency after correction for the nucleotide composition of the BCL-6 region sequenced (T = 27%; C = 19%; G = 28% and A = 26%). 
BCL-6 protein expression in B-CLL
21,24-26
Analysis of IgV H and V L genes
Analysis of IgV H gene sequences in B-CLL revealed a single PCR product corresponding to a rearranged V H gene in 25/28 cases. In two patients (cases GN14 and GN24), two different V H genes were amplified (one V H 1 and one V H 3 gene in both cases). However, sequence analysis disclosed that the V H 3 product of sample GN14 was a non-productive rearrangement probably involving a pseudogene, while the CDR3 region of the V H 1 rearrangement of case GN24 harbored a stop codon. On this basis, both sample GN14 and sample GN24 displayed a single productive rearrangement. Finally, in one patient (case GN16), analysis of IgV H genes yielded no amplimer and, therefore, subsequent analysis of Ig genes was based on the results of V L gene sequences. Fourteen of 27 (52%) B-CLL carried somatically mutated IgV H genes ( 
Discussion
The present analyses resulted in the definition of three genetically distinct groups of B-CLL (Table 1) . Group I B-CLL includes those cases harboring mutations of both BCL-6 and IgV genes. B-CLL belonging to group I represented 36% (10/28) of the samples included in our series. Group II B-CLL displayed mutations of IgV genes in the presence of germline BCL-6 loci (5/28; 18%). Finally, a subset of B-CLL cases (group III; 13/28; 46%) displayed unmutated IgV and BCL-6 genes ( Table 1) .
As also observed in other B cell lymphomas associated with BCL-6 mutations, 13, 18 the presence of BCL-6 mutations in B-CLL was consistently accompanied by mutations of IgV genes. On this basis, and because BCL-6 mutations are acquired during B cell transit through the GC, [13] [14] [15] BCL-6 mutations may provide a marker to differentiate B-CLL cases histogenetically related to post-GC B lymphocytes from B-CLL cases derived from pre-GC B lymphocytes. This distinction may bear clinical implications since B-CLL with post-GC features (ie mutated IgV genes) have a better clinical course then B-CLL with pre-GC features. 3, 4 Conceivably, both group I and group II B-CLL are histogenetically correlated to GC B cells, and the lack of BCL-6 mutations in group II B-CLL may be simply ascribed to the lower efficiency of the BCL-6 mutation mechanism as compared to the efficiency of the IgV somatic hypermutation mechanism normally acting in the GC. [13] [14] [15] 18 Notably, previous studies identified prognostic subgroups of B-CLL based on the presence (group I + group II) or absence (group III) of IgV mutations. 3, 4 Future studies are required to define whether B-CLL with IgV mutations and with or without BCL-6 mutations (group I and group II, respectively) display distinct biological and clinical features. In fact, although group I and group II B-CLL conceivably share a similar histogenesis, the presence of BCL-6 mutations might affect the disease pathogenesis, as suggested by preliminary evidence revealing a biological role for these mutations. 27 Overall, the features of BCL-6 mutations observed in B-CLL are similar to the mutational spectrum of BCL-6 previously reported in normal B cells and in several types of B cell nonHodgkin lymphomas derived from GC or post-GC B cells. [13] [14] [15] [16] [17] [18] Also, it is notable that the mutational pattern of BCL-6 in B-CLL closely reflects the pattern of IgV gene mutations, which are acquired at the time of B cell transit through the GC. In particular, single nucleotide substitutions predominate over insertions/deletions and nucleotide transitions occur more frequently than expected by chance alone (this study and Ref. 18) .
The expression of BCL-6 protein in a fraction of B-CLL is surprising, since BCL-6 expression in normal B cells selectively clusters with the GC stage of differentiation, whereas B-CLL cells are thought to reflect either pre-GC or post-GC B cells. 28, 29 Also, previous studies performed by immunocytochemistry and/or immunohistochemistry failed to detect BCL-6 expression in B-CLL, although in some instances a faint nuclear staining was reported. 21 Several observations may clarify these discrepancies. In this study flow cytometry assay was employed, which may be more sensitive than the usual immunostaining of frozen sections. In this respect, it is worth mentioning that results similar to those reported above were obtained using the antibody PG-B6p which does not detect BCL-6 expression by B-CLL in lymph node sections. 21 Another consideration may concern the fact that B-CLL are activated cells (reviewed in Ref. 30 ) and thus are different from normal follicular mantle B cells that are mostly in a resting state.
Apart from the histogenetic relevance of BCL-6 mutations, indirect observations suggest that these molecular alterations may carry functional consequences. In particular, it is remarkable that BCL-6 mutations cluster in highly conserved genomic regions, suggesting that some mutations harbored by B-CLL may affect regulatory domains of BCL-6 and thus potentially deregulate the expression of the gene. 7, 13, 18 Also, preliminary observations obtained with the transfection of one single multiply mutated BCL-6 allele derived from B cell neoplasms indicate that BCL-6 5Ј mutations may be associated with deregulated transcriptional activity of BCL-6 and that deregulation is caused by a single mutation. 27 Future studies are required to definitively address the precise relevance of BCL-6 mutations in the pathogenesis of B-CLL.
